Brind.

PL Capital remains constructive on domestic equities.

Steady: 0 in the last 7 days Updated oct 23

The latest in this situation

  1. PL Capital initiated coverage with a 'Buy' rating on Sai Lifesciences, citing benefits from increasing pharmaceutical outsourcing.

How it started

1 report, 1 independent, last reported Aug 27. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

PL Capital remains constructive on domestic equities.

How it developed

Newest first. Tap a step to see who reported it.
  1. PL Capital initiated coverage with a 'Buy' rating on Sai Lifesciences, citing benefits from increasing pharmaceutical outsourcing.Sub-event
  2. PL Capital remains constructive on domestic equities.1 source

Coverage

Newest first; wire copies grouped